Alira Health Contributes to 2021 Bioregion Report on the Future of Catalan Life Sciences

Provides Key Trends in Market Access for Pharma and MedTech

Published on:
January 27, 2022


January 27, 2022 – Alira Health, a global healthcare consulting and technology firm, announced that it is a key contributor to the just released 2021 Bioregion Report, the benchmark study that analyzes the life sciences and healthcare sector in Catalonia, conducted by Biocat, BioRegion of Catalonia together with CataloniaBio & HealthTech and ACCIÓ. Alira Health provided an in-depth analysis of market access trends, as well as tools to help understand the phases of market access in different countries, highlighting ways to ensure that the adoption of products (drugs, medical devices) is most effective.

Some key findings from the report –

  • Health startups in the BioRegion raised €238 million in 2021, a new record.
  • Venture capital remains the main source of investment, up 34% from 2020. 83% of the venture capital raised was from international investors.
  • The medical technology subsector attracted the most investment while digital health companies saw investment nearly double from 2020.

This report was promoted by Biocat, CataloniaBio & HealthTech and ACCIÓ on January 25th at an event featuring the President of the Government of Catalonia and representatives from the sector.

Chus Castillo

Chus Castillo Gutierrez

Director of Global Market Access at Alira Health

“We are extremely pleased to contribute to this important annual report on the growth drivers and opportunities in the Catalan life sciences and health care ecosystem,” said Chus Castillo Gutierrez, Director of Global Market Access at Alira Health. “Alira Health has a very strong presence in Catalonia, with over 90 employees in our Barcelona office. We are deeply committed to supporting the growth and transformation of healthcare in Spain. This forward-looking report is an essential read for every healthcare organization who aspires to be a strong player in Catalonia as the region positions itself to be a leading European hub for emerging therapies and personalized medicine.”

About Alira Health

Alira Health is an international patient-centric and technology-enabled advisory firm whose mission is to humanize healthcare. We work with healthcare and life sciences organizations looking for support across their entire solutions lifecycle. From development to medical care, we complement our clients’ expertise with a full spectrum of services including research and clinical development solutions, technology-powered consulting, and real-world evidence.
Our integrated and multidisciplinary team of over 500 scientists, strategists, economists, clinicians, and biostatisticians collaborate across our North American, European, and Asian offices and advise 80% of the top 50% of MedTech companies and 75% of the top 50% of Pharma companies.

Related news

News September 8, 2023
Alira Health Partners With Col·legi de Metges de Barcelona
We are pleased to partner with Col·legi de Metges de Barcelona (CoMB), an institution that represents and serves the almost 39,000 physicians in Barcelona.
Market Access Spain Startups
Events August 10, 2023
12th EPP Life Sciences Pricing Forum
We are excited to speak at the 12th EPP Life Sciences Pricing Forum for pricing directors and executives in Life Sciences.
EU Market Access
Events July 31, 2023
ESMO Congress
We are excited to join the ESMO Congress in Madrid. to disseminate the latest cutting-edge data for oncologists and other stakeholders.
Drug Development Market Access Oncology Spain
Publications July 25, 2023
Improving Access to Medicine: The Role of Pharma Companies in Emerging Markets
Our Market Access experts have identified risks and opportunities associated with improving access to medicines in emerging countries.
Market Access Pharma
Blog June 30, 2023
Why You Need Market Access and How to Get Started
Start reading to learn about the importance of market access in pharma and MedTech and the key steps to get started.
Market Access MedTech Pharma
Blog April 17, 2023
Reimbursement of Rare Disease Drugs in Italy: Challenges and Hopes for the Future
When it comes to rare diseases, Italy has done a good job in bringing EMA-approved drugs, including orphan drugs, to the Italian market. But  multiple challenges exist, many of which(...)
Italy Market Access Pharma Rare Disease Real-World Evidence (RWE)
Blog April 17, 2023
Pharmaceutical Market Access in the UK: A Changing Landscape
Start reading this interview with Rachel Fyson to gain insight into the changing landscape of market access in the United Kingdom.
Market Access Pharma UK
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.